Apellis PharmaceuticalsAPLS
APLS
About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Employees: 702
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 13 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
209% more call options, than puts
Call options by funds: $128M | Put options by funds: $41.5M
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
2% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 92
0% less funds holding
Funds holding: 261 [Q2] → 260 (-1) [Q3]
0.93% less ownership
Funds ownership: 97.16% [Q2] → 96.23% (-0.93%) [Q3]
2% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 44
25% less capital invested
Capital invested by funds: $4.52B [Q2] → $3.38B (-$1.14B) [Q3]
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
28%
downside
Avg. target
$41
23%
upside
High target
$60
80%
upside
13 analyst ratings
6 positive
46%
7 neutral
54%
0 negative
0%
Goldman Sachs Salveen Richter 24% 1-year accuracy 4 / 17 met price target | 8%upside $36 | Neutral Downgraded | 17 Dec 2024 |
Morgan Stanley Judah Frommer 38% 1-year accuracy 3 / 8 met price target | 7%downside $31 | Equal-Weight Initiated | 21 Nov 2024 |
Baird Colleen Kusy 33% 1-year accuracy 7 / 21 met price target | 65%upside $55 | Outperform Maintained | 7 Nov 2024 |
Citigroup Yigal Nochomovitz 22% 1-year accuracy 10 / 46 met price target | 53%upside $51 | Buy Maintained | 6 Nov 2024 |
RBC Capital Luca Issi 23% 1-year accuracy 13 / 56 met price target | 28%downside $24 | Sector Perform Maintained | 6 Nov 2024 |
Financial journalist opinion
Based on 4 articles about APLS published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) on behalf of long-term stockholders following a class action complaint that was filed against Apellis on August 2, 2023 with a Class Period from January 28, 2021 to July 28, 2023. Our investigation concerns whether the board of directors of Apellis have breached their fiduciary duties to the company.
Neutral
GlobeNewsWire
2 weeks ago
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of December 2, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Zacks Investment Research
2 weeks ago
Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
4 weeks ago
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following December investor conferences:
Negative
Zacks Investment Research
1 month ago
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.
Neutral
The Motley Fool
1 month ago
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Sales of the company's top commercialized product didn't meet expectations.
Neutral
Seeking Alpha
1 month ago
Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Meredith Kaya - Senior Vice President of Investor Relations and Strategic Finance Cedric Francois - Co-Founder and Chief Executive Officer Adam Townsend - Chief Operating Officer Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Salveen Richter - Goldman Sachs Yigal Nochomovitz - Citigroup Nicholas Econom - Raymond James Phil Nadeau - TD Cowen Katherine Wang - Jefferies Ellie Merle - UBS Annabel Samimy - Stifel Douglas Tsao - H.C. Wainwright Lachlan Hanbury-Brown - William Blair Derek Archila - Wells Fargo Biren Amin - Piper Sandler Lisa Walter - RBC Greg Harrison - Scotiabank Graig Suvannavejh - Mizuho Securities Laura Chico - Wedbush Securities Operator Good morning, ladies and gentlemen.
Positive
Zacks Investment Research
1 month ago
Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Investors Business Daily
1 month ago
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales
Apellis stock plunged Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations. The post Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales appeared first on Investor's Business Daily.
Negative
Zacks Investment Research
1 month ago
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.17 per share a year ago.
Charts implemented using Lightweight Charts™